What Lilly Reported
On October 28, 2026, Eli Lilly announced topline results from TRANSCEND-T2D-2, the first Phase 3 head-to-head trial pitting its experimental triple agonist retatrutide against semaglutide in adults with type 2 diabetes. Retatrutide acts on three receptors at once, GLP-1, GIP, and glucagon, while the comparator was semaglutide dosed at 2 mg, the formulation marketed as Ozempic. The study ran for 80 weeks and enrolled 1,298 adults.
Topline means the company has released headline numbers ahead of the full dataset. The results have not yet been peer-reviewed, and the detailed figures are expected at a future medical meeting.
The Blood Sugar and Weight Results
On the primary measure of glycemic control, both retatrutide doses lowered A1C by 2.2 percentage points, compared with 1.8 points for semaglutide. The 12 mg dose met the bar for noninferiority and went further to show statistical superiority over semaglutide.
The weight difference was larger. Participants on retatrutide lost 19.5 percent of body weight on the 9 mg dose and 20.9 percent on the 12 mg dose, against 9.4 percent for semaglutide. That is more than double the weight reduction seen with the comparator.
Lilly also reported greater improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure with retatrutide, though it did not release specific numbers for those measures.
The Trade-Off in Tolerability
The stronger efficacy came alongside more side effects. Dysesthesia, an abnormal skin sensation, was reported by 6.5 percent of participants on the 12 mg retatrutide dose versus 2.7 percent on semaglutide. Discontinuations due to adverse events ran at 7.9 percent for retatrutide compared with 2.7 percent for semaglutide, and diarrhea was more common on the triple agonist.
This pattern, more weight loss paired with more gastrointestinal and other effects, is a recurring theme as newer multi-receptor agents are compared with established single-target drugs.
Limitations to Keep in Mind
Two design features temper how far the results can be pushed. The trial was open-label, meaning participants and investigators knew which drug was being given, which can influence reported outcomes and side-effect tracking. And with 1,298 adults, the study is informative but not enormous. These are topline figures, so the complete safety and efficacy picture will only be clear once the full data are published and reviewed.
Why It Matters
A direct comparison against semaglutide, currently one of the most widely used metabolic drugs, is a meaningful benchmark. If the full dataset holds up, retatrutide would represent a step up in both glucose control and weight reduction for type 2 diabetes, with the open question being whether patients and prescribers accept the higher rate of side effects and discontinuations. Regulators will weigh the complete evidence package before any decision.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.